Karen Kaplan is science and medicine editor at the Los Angeles Times. Before joining the science group in 2005, she covered technology in the Business section for 10 years. She is a graduate of MIT and Columbia University. In a parallel universe without journalism, she’d have a career in economics, genetics, biostatistics or some other field that describes the world in math.
Latest From This Author
Just a couple of weeks ago, I wondered whether the coronavirus would take a summer vacation. Now we know the answer: It most certainly will not.
The current virus wave includes the third-highest peak of the pandemic, but hospitalizations are manageable, and deaths aren’t rising out of control.
Experts are unsure if we’ll see a downswing in the virus over the next few months. “This virus throws us curve balls all the time,” noted a scientist.
Why did an ambitious California effort to promote COVID-19 vaccines fizzle out so fast?
Cases are way up in some places. How did we get here? Because Omicron didn’t rest on its laurels. Its subvariants are even nastier than the original.
About 1 in 6 American adults still insist they’re just fine without a COVID-19 vaccine and have no plan to get one. Could Novavax change their minds?
It hardly seemed possible on Feb. 6, 2020, when the first official COVID-19 fatality was recorded in the U.S. that 999,999 others would follow.
The L.A. Police Department said its mask mandate wasn’t just for show: Those who didn’t comply would be held accountable. That doesn’t seem to be happening.
Coachella and Stagecoach tested the hypothesis that if people ignore the coronavirus, it will return the favor.
Even if you wear a top-of-the-line N95 respirator, it won’t be as helpful as a mask on the face of a person who’s infected.